• darkblurbg

    Developing precision therapies

    for type 1 diabetes

  • darkblurbg

    Intralymphatic immunotherapy

    with Diamyd®

The scientific rational and evidence supporting our therapeutic diabetes vaccine Diamyd® was further strengthened the past quarter with three articles published in peer-reviewed scientific journals.

Ulf Hannelius
President and CEO, Diamyd Medical AB
CEO Comments, Quarterly Report 3 21/22

Company Presentation

 June 22, 2022


 Dates for financial information and other events
September 6 − September 7, 2022
LSX Nordic Congress
September 20 − September 23, 2022
EASD 2022
EASD 58th Annual Meeting, Stockholm, Sweden
October 5, 2022
Year-End Report
Year-End Report 2021/2022
November 10, 2022
Annual Report
Annual Report 2021/2022
December 1, 2022
Annual General Meeting
Annual General Meeting 2021/2022


Diamyd Medical develops therapies for type 1 diabetes
The share is listed on Nasdaq First North Growth Market (ticker: DMYD B)

Read More

Order GAD for preclinical research